Evidence-based update of chemotherapy options for metastatic colorectal cancer

ANZ Journal of Surgery
Dragan DamjanovicMichael P N Findlay

Abstract

Colorectal carcinoma is one of the most common malignancies in the Western world. Although fluorouracil (5-FU) has been used for over 40 years, only in the last decade has its value been recognized in the treatment of advanced colorectal cancer. Early randomized studies explored the best possible doses and schedules of 5-FU and its modulators such as folinic acid or leucovorin (LV) in combination with respect to efficacy and side-effects. The development of oral fluoropyrimidines, in particular capecitabine, has made chemotherapy further accessible and acceptable. The introduction of newer cytotoxics irinotecan and oxaliplatin has achieved a significant improvement in survival rates with manageable toxicity. With appropriate selection of patients and proper sequencing of currently most efficient regimens, median survival durations of around 20 months can now be reached. Novel targeted therapies (bevacizumab, cetuximab and cyclooxygenase-2 (COX-2) inhibitors) in combination with most efficient chemotherapy regimens will probably push the median survival beyond the 2-year mark. The present article is an overview of most important studies that have substantially changed the approach to metastatic colorectal cancer and have given t...Continue Reading

References

Jun 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN Nordic Gastrointestinal Tumor Adjuvant Therapy Group
Mar 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M Findlay
Jan 1, 1994·Cancer Treatment Reviews·G J CreemersJ Verweij
May 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Y ShimadaN Ogawa
Mar 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A ContiC Gonzalez
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L RothenbergD D Von Hoff
Jan 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P RossD Cunningham
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P RougierM Mahjoubi
Feb 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A de GramontM Krulik
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN Meta-analysis Group In CancerE Levy
Nov 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN Meta-Analysis Group In CancerP Thirion
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S GiacchettiF Lévi
Feb 16, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T J IvesonE Van Cutsem
Mar 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E Van CutsemJ Verweij
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A de GramontA Bonetti
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Apr 6, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C TwelvesUNKNOWN Xeloda Colorectal Cancer Study Group
May 4, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A Zori CombaA Schmilovich
Sep 18, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L RothenbergS Wadler
Jun 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J SouglakosV Georgoulias
Nov 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B GlimeliusS Pyrhönen
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz KabbinavarEmily Bergsland
Jan 9, 2003·Virchows Archiv : an International Journal of Pathology·UNKNOWN Association of Directors of Anatomic and Surgical Pathology
Feb 14, 2003·Lancet·T S MaughanUNKNOWN Medical Research Council Colorectal Cancer Group
Jun 13, 2003·Seminars in Oncology·Jan Stoehlmacher, Heinz-Josef Lenz
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Dec 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M GoldbergSteven R Alberts

❮ Previous
Next ❯

Citations

Aug 8, 2006·Surgical Oncology·Giovanni Li DestriStefano Puleo
Nov 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guillaume PortierLaurent Bedenne

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.